IRulya Therapeutics posts October 2026 corporate presentation detailing LAM-001 Phase 2 programs and milestones

Amazon.com introduced TorchNeuron, a tool allowing PyTorch code to run on its Trainium AI chips without modification. The company plans to release the software as free and open-source, aiming to challenge Nvidia's dominance in AI computing. Over 30 early customers are using the software, with potential cost savings. Announcement is scheduled for a developer conference on Monday.

H.C. Wainwright reiterated a Buy rating and $10.00 price target for Zentalis Pharmaceuticals (ZNTL) after positive survival data from its DENALI Part 1b trial. The stock has fallen 15% in a week, trading at $2.13. The trial showed cyclin E1-positive patients had a median overall survival of 15.8 months. The company has strong cash reserves and a high current ratio, supporting ongoing trials. Other analysts also initiated coverage with positive ratings and price targets.

Amazon is investing in a nuclear energy plant in Indiana, targeting 960 megawatts of carbon-free energy. This is part of a collaboration with X-energy to add over 5 gigawatts of U.S. nuclear energy by 2039. The project could create over 1,000 construction jobs and 100 permanent roles.

FibroBiologics (FBLG) presented preclinical data at the North American Spine Society Annual Meeting, showing statistically significant improvements in disc height for all fibroblast-treated groups in a 12-week rabbit model. The FSdC spheroid group showed the highest percent disc height index at 80.7% compared to 71.8% in controls. The company develops treatments using fibroblast cells and holds over 270 patents.

FibroBiologics (FBLG) presented preclinical data at the NASS 2026 Annual Meeting, showing its FSdC spheroids preserved disc height better than other fibroblast-based approaches in a 12-week rabbit model of degenerative disc disease. Key findings include significant improvements in disc height and matrix remodeling, with FSdC spheroids showing the highest %DHI of 80.7% compared to 71.8% in controls.

Tempus AI reported >80% sensitivity in its AI NSCLC pre-screening panel across 12 biomarkers, with some >90%, from a 60,459-case analysis presented at ESMO 2026. The tool is in development to prioritize confirmatory testing.